Skip to main content
. 2023 Apr 28;25(6):259. doi: 10.3892/ol.2023.13845

Figure 3.

Figure 3.

Kaplan-Meier analysis of PFS in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in the high-level and low-level CD8+ tumor-infiltrating lymphocytes groups. Significant differences in PFS were determined by the log-rank test. The time 0 was defined as the date of atezolizumab plus bevacizumab administration. PFS, progression-free survival; TILs, tumor-infiltrating lymphocytes; MST, median survival time.